AR081389A1 - Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma. - Google Patents

Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma.

Info

Publication number
AR081389A1
AR081389A1 ARP110101624A ARP110101624A AR081389A1 AR 081389 A1 AR081389 A1 AR 081389A1 AR P110101624 A ARP110101624 A AR P110101624A AR P110101624 A ARP110101624 A AR P110101624A AR 081389 A1 AR081389 A1 AR 081389A1
Authority
AR
Argentina
Prior art keywords
dementia
disease
alzheimer
hemifumarate
difluoromethyl
Prior art date
Application number
ARP110101624A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR081389A1 publication Critical patent/AR081389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a una sal de tipo hemifumarato del compuesto (1S)-1-(2-(difluorometil)piridin-4-iI)-4-fluoro-1-(3-(pirimidin-5-il)fenil)-1H-isoindol-3-amina, a la Forma A de esta y a sus composiciones farmacéuticas. Además, la presente se refiere a métodos terapéuticos para el tratamiento y/o la prevencion de patologías relacionadas con Abeta tales como síndrome de Down, angiopatía beta-amiloide tal como, sin carácter limitante, angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con deficiencia cognitiva tales como, sin carácter limitante, DCL (ôdeterioro cognitivo leveö), enfermedad de Alzheimer, pérdida de memoria, síntomas de déficit de atencion asociados con la enfermedad de Alzheimer, neurodegeneracion asociada con enfermedades tales como la enfermedad de Alzheimer o la demencia, que incluyen la demencia de origen mixto vascular y degenerativo, demencia presenil, demencia senil y demencia asociada con la enfermedad de Parkinson, parálisis supranuclear progresiva o degeneracion corticobasal. Reivindicacion 4: La Forma A del hemifumarato de (1S)-1-(2-(difluorometil)piridin-4-il)-4-fluoro-1-(3-(pirimidin-5-il)fenil)-1H-isoindol-3-amina, que se caracteriza por que proporciona un patron de difraccion de rayos X en polvo que presenta sustancialmente los siguientes picos principales con valores de d: Espaciado d [L] 8.2, 5.3, 4.92, 4.54, 4.37.
ARP110101624A 2010-05-12 2011-05-11 Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma. AR081389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33388310P 2010-05-12 2010-05-12

Publications (1)

Publication Number Publication Date
AR081389A1 true AR081389A1 (es) 2012-08-29

Family

ID=44912284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101624A AR081389A1 (es) 2010-05-12 2011-05-11 Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma.

Country Status (5)

Country Link
US (1) US20110281894A1 (es)
AR (1) AR081389A1 (es)
TW (1) TW201144295A (es)
UY (1) UY33376A (es)
WO (1) WO2011142716A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
MX2013011947A (es) 2011-04-13 2014-01-16 Merck Sharp & Dohme Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
US9365589B2 (en) 2012-12-20 2016-06-14 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use
CN108226319A (zh) * 2016-12-22 2018-06-29 亚宝药业集团股份有限公司 一种检测卡巴拉汀贴剂中光学异构体的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
US20110281894A1 (en) 2011-11-17
WO2011142716A1 (en) 2011-11-17
TW201144295A (en) 2011-12-16
UY33376A (es) 2011-12-30

Similar Documents

Publication Publication Date Title
CO6781485A2 (es) Compuestos y su uso como inhibidores de bace
AR081389A1 (es) Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma.
CU20110106A7 (es) Nuevos compuestos 578
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
MX2010008700A (es) Moduladores de beta-amiloide.
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
IL213259A0 (en) Composition for the use to treat alzheimer's disease
EP2576540A4 (en) HETEROARYLATED COMPOUNDS AND METHODS OF USE
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
CO7151486A2 (es) Sal de tipo camsilato
WO2010018213A3 (en) Spiroimidazole compounds suitable for the treatment of neurological disorders
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
IN2015DN00345A (es)
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
EP2413696A4 (en) COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP3085691A4 (en) Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition
CU20130083A7 (es) Compuestos y su uso como inhibidores de bace
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
IN2013MU01243A (es)
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators
IN2013MU01242A (es)
WO2013114403A8 (en) Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure